AstraZeneca

HUTCHMED entered into a global licensing, co-development, and commercialization agreement with AstraZeneca to develop savolitinib, a c-Met inhibitor marketed in China under the brand name ORPATHYS®.

Development costs for savolitinib in China are shared between HUTCHMED and AstraZeneca, with HUTCHMED continuing to lead the development in China. AstraZeneca leads and funds the development of savolitinib for the rest of the world. HUTCHMED received an upfront payment and is entitled to further payments contingent on the successful achievement of clinical development and first sale milestones. The agreement also contains possible future commercial sale milestones, a fixed royalty on all sales in China and double-digit tiered royalties on all sales made outside of China.

Eli Lilly

HUTCHMED entered into a licensing, co-development and commercialization agreement in China with Lilly for fruquintinib, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase marketed in China under the brand name ELUNATE®.

Under the terms of the agreement, the costs of future development of fruquintinib in China, carried out by HUTCHMED, are shared between HUTCHMED and Lilly. HUTCHMED has received upfront payments, as well as development and regulatory approval milestone payments and double-digit tiered royalties. HUTCHMED manufactures the product and manages all on-the-ground medical detailing, promotion and local and regional marketing activities in China.

Takeda

HUTCHMED entered into an exclusive license agreement with Takeda to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau, where it is licensed to Eli Lilly and Company.

HUTCHMED received an upfront payment and is eligible to receive additional potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales.

Ipsen

HUTCHMED entered into a collaboration with Ipsen subsidiary Epizyme to research, develop, manufacture and commercialize tazemetostat (marketed in the US under the brand name TAZVERIK®) in Greater China. This collaboration is designed to accelerate global development in mono and in combination therapy, including the investigation of tazemetostat combinations with our novel oncology medicines portfolio.

Under the terms of the agreement, we are developing tazemetostat in various hematological and solid tumors in Greater China. We are also participating in the Ipsen-led global registrational study of tazemetostat in combination with R² in second line follicular lymphoma, leading the study in Greater China. Upon any approvals we will be responsible for commercialization in Greater China.

Inmagene

HUTCHMED and Inmagene entered into a strategic partnership to further develop several novel preclinical drug candidates discovered by HUTCHMED for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies worked together to move the drug candidates towards IND submission. Inmagene then move the drug candidates through global clinical development.

Under the terms of the agreement, HUTCHMED grants Inmagene exclusive options to the drug candidates solely for the treatment of immunological diseases. Should Inmagene exercise the option, it will have the right to further develop, manufacture and commercialize that specific drug candidate worldwide, with HUTCHMED retaining first right to co-commercialization in mainland China. For each of the drug candidates, HUTCHMED will be entitled to development milestones and commercial milestones payments, as well as up to double-digit royalties upon commercialization.

Innovent

Innovent Biologics is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. Its product portfolio includes Tyvyt® (sintilimab injection), an anti-PD-1 monoclonal antibody co-developed with Eli Lilly, which received marketing approval in China.

We entered into a collaboration agreement with Innovent Biologics to evaluate the safety, tolerability and efficacy of fruquintinib in combination with sintilimab.

Junshi

Shanghai Junshi Biosciences is a biopharmaceutical company based in Shanghai, China that focuses on discovering, developing and commercializing innovative drugs.

We entered into a collaboration agreement with Junshi to evaluate the safety, tolerability and efficacy of surufatinib in combination with toripalimab, a PD-1 monoclonal antibody approved for marketing in China.

BeiGene

BeiGene is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Its product portfolio includes the anti-PD-1 antibody tislelizumab.

We entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of HUTCHMED's drug candidates, surufatinib and fruquintinib, with tislelizumab, for the treatment of various solid tumor cancers.

PLEASE NOTE:

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.